Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Collegium Pharmaceutical (COLL) Revenue (2016 - 2026)

Collegium Pharmaceutical has reported Revenue over the past 10 years, most recently at $205.4 million for Q4 2025.

  • For Q4 2025, Revenue rose 12.92% year-over-year to $205.4 million; the TTM value through Dec 2025 reached $780.6 million, up 62.58%, while the annual FY2025 figure was $780.6 million, 23.62% up from the prior year.
  • Revenue for Q4 2025 was $205.4 million at Collegium Pharmaceutical, down from $209.4 million in the prior quarter.
  • Over five years, Revenue peaked at $209.4 million in Q3 2025 and troughed at $3.6 million in Q1 2022.
  • A 5-year average of $125.0 million and a median of $136.1 million in 2023 define the central range for Revenue.
  • Biggest five-year swings in Revenue: crashed 95.86% in 2022 and later surged 3882.59% in 2023.
  • Year by year, Revenue stood at $38.3 million in 2021, then skyrocketed by 238.18% to $129.6 million in 2022, then rose by 15.53% to $149.7 million in 2023, then grew by 21.51% to $181.9 million in 2024, then increased by 12.92% to $205.4 million in 2025.
  • Business Quant data shows Revenue for COLL at $205.4 million in Q4 2025, $209.4 million in Q3 2025, and $188.0 million in Q2 2025.